Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz3. fázis

MHB018A Treatment in Patients With Chronic Thyroid Eye Disease

A legfontosabb adatok

Ki végzi
Minghui Pharmaceutical (Hangzhou) Ltd
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Fut, nem toboroz
Fázis
3. fázis
Résztvevők
150 fő, tervezett
Kezdés
2026. márc. 17.
Várható befejezés
2028. aug. 31.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • MHB018A injection
  • MHB018A injection Placebo
A regiszteradat frissítve
2026. szeptember 24.

Ki vehet részt

Életkor
18 év – 75 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 32 feltétel megnézéseKevesebb

Ki vehet részt

  • Subjects voluntarily participating in the study and signing the informed consent form
  • Aged 18-75 years (inclusive), of any gender
  • Clinical diagnosis of chronic Thyroid Eye Disease (TED) , with symptoms in the study eye more than 12 months and less than 10 years
  • Subjects with a clinical diagnosis of moderate to severe TED at screening and baseline
  • Does not require immediate surgical ophthalmological intervention, and no corrective surgery/orbital radiotherapy is planned during the study
  • Diabetic subjects must have well-controlled stable disease
  • Sufficient bone marrow and organ function
  • Eligible subjects of childbearing potential (male and female) must agree to use reliable contraceptive methods; female subjects of childbearing potential must have a negative blood pregnancy test within 7 days before the first use of the study drug and must not be breastfeeding
  • Subject is willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the study; -

Ki nem vehet részt

  • Subjects who have previously received orbital radiotherapy or ophthalmic surgery for TED
  • Subjects who received oral or intravenous corticosteroids or corticosteroid eye drops/ointments for TED within 4 weeks before the first dose; subjects who received periorbital/orbital steroid injections within 3 months before the first dose
  • Subjects who used oral or intravenous corticosteroids for reasons other than TED within 4 weeks prior to Screening, excluding local use (topical, nasal, inhalation)
  • Any previous treatment with rituximab, tocilizumab, other immunosuppressive agent use within 3 months prior to Screening
  • Previous treatment targeting IGF-1R
  • Selenium and biotin must be discontinued 3 weeks prior to Screening and must not be restarted during the trial; however, taking a multivitamin that includes selenium and/or biotin is allowed
  • Use of an investigational agent for any condition within 30 days prior to Screening or anticipated use during the course of the trial
  • Acute cardiovascular disease history or treatment within 6 months before the first dose
  • Drug or alcohol abuse during the screening period
  • Subjects who received or planned to receive live or attenuated live vaccines within 4 weeks before the first dose or during the study period
  • Subjects who underwent major surgery within 4 weeks before the first dose or are expected to undergo surgery during the study period or within 4 weeks after the study
  • Known hypersensitivity to any of the components of MNB018A or prior hypersensitivity reactions to mAbs; -
  • Identified pre-existing ophthalmic disease that, in the judgment of the Investigator, would preclude study participation or complicate interpretation of study results
  • Malignant condition in the past 5 years before signing the ICF (except successfully treated basal/squamous cell carcinoma of the skin)
  • Presence of poorly controlled hypertension with systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg; Renal artery stenosis
  • Hearing impairment history in either ear during the screening period; or abnormal pure tone audiometry results
  • Biopsy-proven or clinically suspected inflammatory bowel disease
  • Positive results for serum virology tests (defined as pos
  • Decreased best corrected visual acuity due to optic neuropathy as defined by a decrease in vision within the last 6 months of two lines of Snellen chart, new visual field defect or color defect secondary to optic nerve involvement
  • Corneal decompensation unresponsive to medical management
  • Decrease in CAS of ≥ 2 points or decrease in proptosis of ≥ 2 mm between screening and baseline
  • Free thyroxine (FT4) and free triiodothyronine (FT3) levels <50% above or below the normal reference range at screening
  • Pregnant or lactating women

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The primary objective of this study is to investigate the efficacy, safety, and tolerability of MHB018A, a humanized anti-IGF1R antibody, administered Q4W for 6 months, in comparison to placebo, in the treatment of participants suffering from chronic TED.

A vizsgálat 2 csoportja

  • MHB018A InjectionA vizsgált kezelés

    subcutaneous injections of MHB018A injection, 450mg once every 4 weeks (q4w).

  • MHB018A Injection PlaceboPlacebo, összehasonlításként

    subcutaneous injections of MHB018A placebo once every 4 weeks (q4w)

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of MHB018A Injection in Subjects With Chronic Moderate-to-Severe Thyroid Eye Disease.
A regiszteradat frissítve
2026. szeptember 24.